Literature DB >> 2918589

Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.

L M Lee1, R W Stevenson, G Szasz.   

Abstract

The use of intracavernous prostaglandin E1 was studied in 48 organically impotent men. Eight men with previous chemical priapism did not have chemically induced priapism at up to 4 times the minimum effective dose of prostaglandin E1. Of 15 men with arteriogenic impotence who had failed prior intracavernous phentolamine and papaverine therapy 10 had adequate erections with prostaglandin E1. A total of 25 men received intracavernous prostaglandin E1 and phentolamine plus papaverine in a double-blind fashion. Erections with prostaglandin E1 were equal or superior to those with phentolamine plus papaverine in each case.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2918589     DOI: 10.1016/s0022-5347(17)40889-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Comparative tolerability and efficacy of treatments for impotence.

Authors:  W Meinhardt; R F Kropman; P Vermeij
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

2.  Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.

Authors:  Dejan Bratus; Gregor Hlebic; Tine Hajdinjak
Journal:  Croat Med J       Date:  2007-02       Impact factor: 1.351

Review 3.  Intracavernous prostaglandin E1 in erectile dysfunction.

Authors:  O I Linet; L L Neff
Journal:  Clin Investig       Date:  1994-01

Review 4.  Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.

Authors:  Kalyana C Nandipati; Rupesh Raina; Ashok Agarwal; Craig D Zippe
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

Review 6.  Impotence in elderly men.

Authors:  J E Morley; F E Kaiser
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

7.  Sex and disability are not mutally exclusive. Evaluation and management.

Authors:  G Szasz
Journal:  West J Med       Date:  1991-05

Review 8.  Oral and injectable medications for the treatment of erectile dysfunction.

Authors:  C C Carson
Journal:  Curr Urol Rep       Date:  2000-12       Impact factor: 2.862

9.  Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation.

Authors:  Sue W Goldstein; Joshua R Gonzalez; Catherine Gagnon; Irwin Goldstein
Journal:  Sex Med       Date:  2016-04-15       Impact factor: 2.491

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.